NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma

被引:34
作者
Seymour, Frances [1 ,4 ]
Cavenagh, Jamie D. [2 ]
Mathews, Janet [3 ]
Gribben, John G. [2 ,3 ]
机构
[1] Leeds Teaching Hosp Trust, Leeds Canc Ctr, Dept Haematol, Leeds, England
[2] St Bartholomews Hosp, Barts Hlth NHS Trust, Dept Haemato Oncol, London, England
[3] Queen Mary Univ London, Barts Canc Inst, Ctr Haemato Oncol, London, England
[4] St James Hosp, Leeds Canc Ctr, Dept Haematol, Leeds LS9 7TF, England
关键词
NATURAL-KILLER-CELL; MULTIPLE-MYELOMA; NKG2D; PD-1/PD-L1; EXPRESSION; TARGET;
D O I
10.1182/bloodadvances.2022007905
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Natural killer (NK) cells are the key cells of the innate immune system that share many characteristics with T lymphocytes; their activation, however, is based on the integration of a range of activatory and inhibitory signals via receptors recognizing recurrent pathogen-associated molecular patterns. Two important populations of NK cells with differing functions are recognized: CD56bright and CD56dim. NK cells have the potential to recognize and kill malignant plasma cells, which offers therapeutic opportunities. We used mass cytometry to examine the phenotype and function of NK cell subsets from patients with newly diagnosed multiple myeloma (NDMM). We show that NK cells in NDMM are shifted toward a CD56bright but dysfunctional cytotoxic phenotype, which exhibits selective loss of cytokine production. The CD56dim subset has features of exhaustion with impaired proliferation, upregulation of programmed cell death protein 1, and loss of T-cell immunoglobulin and mucin domain 3 expression. Poor expression of NK cell activation markers is seen and is associated with inferior long-term survival. These results suggest that NK cell exhaustion is already present by the time of myeloma diagnosis and likely contributes to the loss of immunologic control of malignant plasma cells. Restoring NK cell function via immune-directed therapies offers a route to restoring immunologic control in multiple myeloma.
引用
收藏
页码:5152 / 5159
页数:8
相关论文
共 21 条
[1]   viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia [J].
Amir, El-ad David ;
Davis, Kara L. ;
Tadmor, Michelle D. ;
Simonds, Erin F. ;
Levine, Jacob H. ;
Bendall, Sean C. ;
Shenfeld, Daniel K. ;
Krishnaswamy, Smita ;
Nolan, Garry P. ;
Pe'er, Dana .
NATURE BIOTECHNOLOGY, 2013, 31 (06) :545-+
[2]   The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody [J].
Benson, Don M., Jr. ;
Bakan, Courtney E. ;
Mishra, Anjali ;
Hofmeister, Craig C. ;
Efebera, Yvonne ;
Becknell, Brian ;
Baiocchi, Robert A. ;
Zhang, Jianying ;
Yu, Jianhua ;
Smith, Megan K. ;
Greenfield, Carli N. ;
Porcu, Pierluigi ;
Devine, Steven M. ;
Rotem-Yehudar, Rinat ;
Lozanski, Gerard ;
Byrd, John C. ;
Caligiuri, Michael A. .
BLOOD, 2010, 116 (13) :2286-2294
[3]   Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells [J].
Bernal, Monica ;
Garrido, Pilar ;
Jimenez, Pilar ;
Carretero, Rafael ;
Almagro, Manuel ;
Lopez, Pilar ;
Navarro, Pilar ;
Garrido, Federico ;
Ruiz-Cabello, Francisco .
HUMAN IMMUNOLOGY, 2009, 70 (10) :854-857
[4]   HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells [J].
Carbone, E ;
Neri, P ;
Mesuraca, M ;
Fulciniti, MT ;
Otsuki, T ;
Pende, D ;
Groh, V ;
Spies, T ;
Pollio, G ;
Cosman, D ;
Catalano, L ;
Tassone, P ;
Rotoli, B ;
Venuta, S .
BLOOD, 2005, 105 (01) :251-258
[5]   Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56BrightCD16- cells and display an impaired capability to kill tumor cells [J].
Carrega, Paolo ;
Morandi, Barbara ;
Costa, Roberta ;
Frumento, Guido ;
Forte, Giuseppe ;
Altavilla, Giuseppe ;
Ratto, Giovanni Battista ;
Mingari, Maria Cristina ;
Moretta, Lorenzo ;
Ferlazzo, Guido .
CANCER, 2008, 112 (04) :863-875
[6]   Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study [J].
Dimopoulos, Meletios A. ;
Lonial, Sagar ;
White, Darrell ;
Moreau, Philippe ;
Weisel, Katja ;
San-Miguel, Jesus ;
Shpilberg, Ofer ;
Grosicki, Sebastian ;
Spicka, Ivan ;
Walter-Croneck, Adam ;
Magen, Hila ;
Mateos, Maria-Victoria ;
Belch, Andrew ;
Reece, Donna ;
Beksac, Meral ;
Spencer, Andrew ;
Oakervee, Heather ;
Orlowski, Robert Z. ;
Taniwaki, Masafumi ;
Roellig, Christoph ;
Einsele, Hermann ;
Matsumoto, Morio ;
Wu, Ka Lung ;
Anderson, Kenneth C. ;
Jou, Ying-Ming ;
Ganetsky, Alex ;
Singhal, Anil K. ;
Richardson, Paul G. .
BLOOD CANCER JOURNAL, 2020, 10 (09)
[7]   Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma [J].
Dimopoulos, Meletios A. ;
Dytfeld, Dominik ;
Grosicki, Sebastian ;
Moreau, Philippe ;
Takezako, Naoki ;
Hori, Mitsuo ;
Leleu, Xavier ;
LeBlanc, Richard ;
Suzuki, Kenshi ;
Raab, Marc S. ;
Richardson, Paul G. ;
McKiver, Mihaela Popa ;
Jou, Ying-Ming ;
Shelat, Suresh G. ;
Robbins, Michael ;
Rafferty, Brian ;
San-Miguel, Jesus .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (19) :1811-1822
[8]   The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells [J].
El-Sherbiny, Yasser M. ;
Meade, Josephine L. ;
Holmes, Tim D. ;
McGonagle, Dennis ;
Mackie, Sarah L. ;
Morgan, Ann W. ;
Cook, Gordon ;
Feyler, Sylvia ;
Richards, Stephen J. ;
Davies, Faith E. ;
Morgan, Gareth J. ;
Cook, Graham P. .
CANCER RESEARCH, 2007, 67 (18) :8444-8449
[9]   Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma [J].
Fauriat, C ;
Mallet, F ;
Olive, D ;
Costello, RT .
LEUKEMIA, 2006, 20 (04) :732-733
[10]   Regulation of human NK-cell cytokine and chemokine production by target cell recognition [J].
Fauriat, Cyril ;
Long, Eric O. ;
Ljunggren, Hans-Gustaf ;
Bryceson, Yenan T. .
BLOOD, 2010, 115 (11) :2167-2176